|Trial status||Trial open for recruitment|
Interventional with experimental drug
|Phase||Trial phase 3|
|Sponsor||Institut Jules Bordet|
|Inclusion criteria||*Radiological progression RECIST 1.1 over the last 12 months*Disease progression on a PET/CT or SPECT/CT over the last 12 months*at least one lesion with hight tumour uptake on Ga-octreotate PET/CT and morphologically measurable according to RECIST1.1|
Watch the video and discover the major project for the new Jules Bordet Institute. Magnificent images of the construction work on the 80,000 m² dedicated exclusively to cancer are accompanied by explanations on how the project was conceived to combine excellence of patient care with optimal well-being for patients and care staff.